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A B S T R A C T
Percutaneous coronary intervention (PCI) is effective in opening the infarct related artery and restoring
thrombolysis in myocardial infarction ﬂow 3 (TIMI-ﬂow 3) in large majority of ST-elevation myocardial
infarction (STEMI). However there remain a small but signiﬁcant proportion of patients, who continue to
manifest diminished myocardial reperfusion despite successful opening of the obstructed epicardial
artery. This phenomenon is called no-reﬂow. Clinically it manifests with recurrence of chest pain and
dyspnea and may progress to cardiogenic shock, cardiac arrest, serious arrhythmias and acute heart
failure. No reﬂow is regarded as independent predictor of death or recurrent myocardial infarction. No
reﬂow is a multi-factorial phenomenon. However micro embolization of atherothrombotic debris during
PCI remains the principal mechanism responsible for microvascular obstruction. This review
summarizes the pathogenesis, diagnostic methods and the results of various recent randomized trials
and studies on the prevention and management of no-reﬂow.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Primary percutaneous coronary intervention (PPCI) is the gold
standard of treatment of ST segment elevation myocardial
infarction (STEMI).1 PPCI restores thrombolysis in myocardial
infarction ﬂow 3 (TIMI 3) in over 90% of patients. However there
remain a small proportion of patients, who continue to exhibit
overt impairment of myocardial reperfusion despite successful
opening of infarct related epicardial artery (IRA). This phenomenon
is called no-reﬂow, which is largely because of severe microvas-
cular obstruction (MVO). Sudden loss of epicardial ﬂow followingAbbreviations: CFR, coronary ﬂow reserve; CFV, coronary ﬂow velocity; CMRI,
cardiac magnetic resonance imaging; CTFC, corrected TIMI frame count; ICCU,
intensive coronary care unit; IMH, intra myocardial/mural hemorrhage; IPC,
ischemic pre-conditioning; IRA, infarct related artery; IS, infarct size; IVUS,
intravascular ultrasound; LV, left ventricle; MACE, major adverse cardiovascular
event; MBG, myocardial blush grade; MCE, myocardial contrast echocardiography;
MPV, mean platelet volume; MVO, microvascular obstruction; OCT, optical
coherence tomography; PCI, percutaneous coronary intervention; PET, positron
emission tomography; PLR, platelet lymphocyte ratio; PPCI, primary percutaneous
coronary intervention; ROC, receiver operating characteristics/curve; STEMI, ST-
elevation myocardial infarction; STR, ST-segment resolution; TIMI, thrombolysis in
myocardial infarction; TMPG, TIMI myocardial perfusion grade.
* Corresponding author at: Flat No 403, Golden Sobhagya, B-81, Rajendra Marg,
Bapu Nagar, Jaipur 15, India. Tel.: +91 9829051103.
E-mail address: gupta98tanya@gmail.com (S. Gupta).
http://dx.doi.org/10.1016/j.ihj.2016.04.006
0019-4832/ 2016 Cardiological Society of India. Published by Elsevier B.V. This is an
licenses/by-nc-nd/4.0/).ballooning or stenting may also occur in incomplete lesion dilation,
epicardial vascular spasm, epicardial dissection or in situ
thrombosis. These procedural failures are totally different clinical
events and need careful exclusion. No reﬂow in human has a
negative effect on the clinical outcome negating the potential
beneﬁt of PPCI in STEMI.2–4 Indeed no reﬂow is regarded as an
independent predictor of death and myocardial infarction.5–7
No reﬂow may set in soon after completion of PCI (within 1–2 h).
Recognition of no reﬂow is essential if it occurs in the catheterization
laboratory (cath lab).8 Ideally the patient should not leave the cath
lab unless no reﬂow has been satisfactorily managed. Clinically no
reﬂow may present with the recurrence of chest pain, cardiogenic
shock with hypotension, malignant arrhythmias or acute dyspnea
due to pulmonary edema secondary to heart failure. No reﬂow is a
progressive phenomenon and its presentation may be delayed.
Angiographic no reﬂow after PCI is associated with reduced
myocardial salvage, larger infarct size and increased long term
5 year mortality.9 Early detection, preventive measures and
treatment of no reﬂow may alter the ﬁnal outcome of PCI.
2. Classiﬁcation
Galiuto10 proposed a pathological classiﬁcation of no reﬂow,
which is deﬁned as inability to reperfuse a region of myocardium
under prolonged ischemia despite re-opening of infarct related open access article under the CC BY-NC-ND license (http://creativecommons.org/
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therapeutic options of no reﬂow.
2.1. Structural no reﬂow
Microvessels within the necrotic myocardium region under
prolonged ischemia exhibit (a) damage and loss of capillary integrity
with endothelial swelling and odema and (b) microvascular
obstruction. Structural no reﬂow is largely irreversible. The extent
of lesion depends upon the severity and duration of ischemia.
2.2. Functional no reﬂow
Patency of microvasculature is compromised due to spasm,
microthrombotic embolization and reperfusion injury, with
accumulation of neutrophils and platelets with activation of
neurohumoral system. Functional no reﬂow may be reversible to a
varying degree.
3. Incidence
No reﬂow is an under-reported complication. A low incidence of
1–3% has been recorded in large registries based on TIMI ﬂow
grade, myocardial blush grade and ST resolution.11 Modern more
sensitive methods of assessing no reﬂow and microcirculatory
dysfunction include myocardial contrast echocardiography (MCE)
and cardiac magnetic resonance imaging (CMRI), which have
recorded a higher incidence (10–30%). Fortunately no reﬂow may
resolve in due course of time in as many as 50% patients.10
However, the immediate prognosis of no reﬂow often remains
uncertain and grave especially in cath lab.
4. Pathogenesis
The goal of reperfusion therapy by percutaneous coronary
intervention in acute myocardial infarction is to restore optimal
blood ﬂow in the infarct related artery (IRA) in order to ensure
adequate blood supply to the ischemic but yet viable myocardium
and to reduce infarct size and mortality. In no reﬂow, myocardial
reperfusion is not achieved inspite of patent IRA. No reﬂow is a
multifactorial phenomenon and ﬁve mechanisms have been
recognized (Niccoli et al.)12: (i) pre-existing microvascular
dysfunction, (ii) distal micro-thrombo-embolization, (iii) ischemic
injury, (iv) reperfusion injury and (v) individual susceptibility. All
these factors are inter-related in a complex manner (Fig. 1).Path ogenesis  of N 
Fig. 1. Pathogenesis of no reﬂow.
ACS, acute coronary syndrome; DM, diabetes mellitus; MVO, microvascular obstructio
(Adapted from Niccoli et al.12,22)4.1. Pre-existing microvascular dysfunction
MVO may be either structural or functional or both. MVO
impairs coronary ﬂow reserve (CFR) and increases the vulnerability
of affected myocardium to the PCI induced injury. Thus the beneﬁts
of re-opening of the obstructed epicardial artery are greatly
compromised by pre-existing microvascular dysfunction. Pre-
existing MVO may be related to advancing age, abnormal insulin
resistance and lipid metabolism (diabetes and hyperlipidemia),
chronic inﬂammatory diseases and individual susceptibility.12
Endothelial dysfunction is regarded as an independent predictor of
adverse cardiac events.13–15
4.2. Distal micro-thrombo-embolization
Micro-embolism during PCI is a predominant cause of no-
reﬂow in humans. Micro-thrombo-emboli refer to thrombus debris
or micro-material from ﬁssured and ruptured atheromatous
plaques from the infarct related artery (IRA) going downstream
during balloon dilatation or stenting. Myocardial perfusion starts
falling, when embolic microspheres block >50% of coronary
capillaries (Niccoli et al.).12 During PCI, 0–25 microspheres may
travel downstream without causing MVO. The number and size of
micro-emboli may vary in different individuals. When the number
>25–200 or the size of micro-emboli is >200 mm, it can cause
severe MVO. Thrombus burden and plaque erosions can be
assessed by intra-vascular ultrasound (IVUS) and optical coher-
ence tomography (OCT).
4.3. Ischemic injury
Kloner et al.16 demonstrated that temporary ligation of coronary
artery in dogs for a period of >90 min resulted in ischemic
anatomical changes in the capillaries of ischemic zone. These were
seen by electron microscopy, which revealed signiﬁcant capillary
damage in the form of swollen endothelial cells with intra-luminal
protrusions and platelet and ﬁbrin thrombi. These changes were
followed by occurrence of endothelial gaps and loss of integrity of
capillary wall with extravascular collection of erythrocytes.
4.4. Reperfusion injury
The purpose of reperfusion is to reverse the ill-effects of
ischemia. However, when ischemia >3 h, reperfusion may aggra-
vate endothelial injury. Reperfusion leads to massive inﬁltration ofo-Reflow 
Distal  Thromboem boli sm 
(rath er usual) 
Ischemic  Injury  (ACS) 
Reperfusio n In jury (Variable) 
Individual  suscepbil ity (DM, 
Hyperlipidemia , Pla telet Abn, 
Genec, Pre-Condi oning)  
Pre-exi sng MVO 
n.
Table 1
Predictors of no reﬂow.
STEMI, ST elevation myocardial infarction; WBC, white blood count; HDL, high density cholesterol; OCT, optical coherence tomography; IVUS, intravascular ultrasound.
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S. Gupta, M.M. Gupta / Indian Heart Journal 68 (2016) 539–551542ischemia zone with neutrophils and platelets. Activated neutro-
phils produce potent vasoconstrictors and inﬂammatory media-
tors, which release oxygen free radicals from the mitochondria.
These result in release of adhesion molecules and bio-active factors
including nitric oxide, prostacyclins and endothelins.17,18 Com-
bined together the ischemia and reperfusion injuries favour intra-
myocardial hemorrhage (IMH) which has been demonstrated by
cardiac magnetic resonance imaging (CMRI) in up to 40% patients
with no-reﬂow.19 IMH is closely related to infarct size (IS) and is a
predictor of severe MVO and adverse clinical outcome.20
4.5. Individual susceptibility
This could be genetic and acquired.
(a) Genetic factors may modulate adenosine-induced vasodilata-
tion. Genetic variation and sex-speciﬁc allelic variant genes
have been recently linked with microvascular dysfunction.21
(b) Individual susceptibility is also inﬂuenced by ischemic pre-
conditioning (IPC). Pre-infarction angina may be helpful in
preventive MVO after PCI.22
(c) Usual well known risk factors for atherosclerosis (e.g. diabetes,
hyperlipidemia, hypertension, etc.) may also have a role in
microvascular dysfunction. Exact mechanisms need further
elucidation.
(d) Baseline reactivity of inﬂammatory cells may modulate the
severity of no reﬂow but a recent study failed to demonstrate
any signiﬁcant association between systemic inﬂammation
and no reﬂow.23
5. Predictors of no reﬂow
Several recent studies have investigated clinical predictors of no
reﬂow in patients with STEMI treated with primary PCI. A few
studies are summarized in Table 1. White blood cell (WBC) count,
thrombus grade/score, age 60 years, mean platelet volume
(MPV), duration between onset of chest pain and PCI (4 h),
hyperglycaemia and raised serum creatinine were a few pre-
dictors.24,25 Wang et al.26 in their study of 1776 STEMI patients
worked out a risk scoring system based on a 7 parameters by
multivariate analysis. Deﬁnite scoring number was given to each
parameter e.g. high neutrophil count 8800/cm3 – 8 points; age
55 years – 5points; thrombus grade 2–5 points, high blood
sugar 12 mmol/L – 4 points; prolonged chest pain before PCI 4 h
– 2 points; high Killip Class IV – 3 points and collateral circulation
1–2 points respectively. All the variable points were added to
build a ﬁnal risk score of no reﬂow. Overall score for patients
ranged from 0 to 29. The optimum cut off score was 14
(sensitivity 76% and speciﬁcity 70.8%). Receiver operating char-
acteristics (ROC) analysis demonstrated a good risk prediction with
area under curve static of 0.800 (95% conﬁdence interval: 0.7772–
0.826). The authors concluded that incidence of no reﬂow may be
predicted with an acceptable accuracy with score higher than
14. Platelet lymphocyte ratio (PLR) on admission was a strong
predictor of no reﬂow in a recent study of Topark et al.27
In a recent publication on the morphological predictors for no
reﬂow after PPCI in STEMI patients, Soeda et al.28,29 studied
145 patients with STEMI who underwent optical coherence
tomography (OCT) and intravascular ultrasound (IVUS) within
12 h of symptoms onset. The authors identiﬁed 72 patients, who
had plaque rupture as the cause for STEMI. These 72 patients
comprised of 28 patients with no reﬂow (38%) and 44 patients
(62%) without no reﬂow. Receiver operating curve (ROC) analysis
revealed OCT derived lipid index <3500 (area under curve 0.77,
p < 0.001) and IVUS derived plaque burden >81.5% (area undercurve 0.70, p = 0.002) were the best morphological discriminators
for no reﬂow. Mazhar et al.30 studied PCI data base of the Canberra
Hospital, Australia and identiﬁed 781 STEMI patients, who
underwent PPCI and observed 189 patients with no reﬂow. By
multivariate analysis to determine the predicting factors of no
reﬂow, the authors found that age 60 years, thrombus score 4
and duration between chest pain and PCI > 360 min were the
principal predictors of no reﬂow. No reﬂow was also associated
with a higher mortality at 12 months follow-up.
6. Diagnostic methods
6.1. Coronary angiography
This is the simplest method to diagnose no reﬂow in the cath
lab. After successful PCI, the dye ﬂows instantaneously into the
infarct related artery (IRA). Many simple and complex angio-
graphic algorithms have been described including thrombolysis in
myocardial infarction (TIMI) ﬂow, corrected TIMI frame count
(CTFC), TIMI myocardial perfusion grade (TMPG) and myocardial
blush grade (MBG).31–33 However, in practice, TIMI ﬂow grade and
MBG are most commonly used. TIMI ﬂow refers to the intensity
and extent of visualization of IRA and the speed of ﬂow of dye. TIMI
ﬂow is graded 0–3. MBG refers to the intensity of radio-opacity of
the myocardial tissue and the speed, with which the enhancement
clears. The ﬁlling appears as a myocardial blush, a ground glass
appearance of the myocardium on the coronary angiogram. MBG is
also graded as 0–3. TMPG is used to characterize the ﬁlling and
clearance of the myocardial perfusion. The ﬁlling appears as
myocardial blush (or ground glass appearance of the myocardium).
TMPG deﬁnes the intensity of the blush and then focuses on the
clearance of the contrast opacity from the myocardium. TMPG is
graded 0–3.31
Thus TIMI ﬂow grading and CTFC evaluate the epicardial ﬂow,
while MBG and TMPG evaluate the microvascular ﬂow. TIMI ﬂow
grading and MBG are used together to deﬁne angiographic no
reﬂow as TIMI ﬂow <3 (with any MBG grade) or TIMI ﬂow 3 with
MBG 0–1.22 Successful reperfusion is TIMI ﬂow 3 with MBG 2/3.
6.2. Electrocardiography (ECG) (ST segment resolution-STR)
Study of STR in serial ECG is a bedside method of assessing
myocardial perfusion following PCI. A rapid decrease of ST
elevation is highly suggestive of reperfusion. STR at 60 min after
PCI should exceed 70%. STR <70% at 60 min is a marker of no
reﬂow.34–36 A rapid decrease of ST segment is highly speciﬁc (91%)
and fairly sensitive (77%) parameter of myocardial reperfusion.
6.3. Intracoronary guidewires
(i) Intracoronary Doppler guidewire is used to measure coronary
ﬂow velocity (CFV) and coronary ﬂow reserve (CFR). These
parameters are regarded as standard methods for assessing
micro vascular function. Three characteristic components are
seen in no reﬂow37: (a) systolic ﬂow reversal, (b) reduced
systolic antegrade ﬂow and (c) forward diastolic ﬂow with
rapid deceleration slope. Coronary blood ﬂow velocity patterns
of no reﬂow are caused by severe capillary damage associated
with increased capillary resistance.38,39 Doppler guidewire can
detect showers of micro-emboli and help in calculation of
micro-circulatory index.
(ii) Intracoronary pressure measurement: a double lumen catheter
with a side hole is employed to measure intracoronary pressure
gradient in IRA. Absence of pressure gradient indicates absence
of obstruction in IRA. By using pressure/thermistor guidewire
placed distally in IRA, index of micro-circulatory resistance
S. Gupta, M.M. Gupta / Indian Heart Journal 68 (2016) 539–551 543(IMR) can be calculated which is related to acute microvascular
damage in no reﬂow.
6.4. Myocardial contrast echocardiography (MCE)
MCE has been regarded as one of the best methods to predict no
reﬂow.40–43 MCE is performed by injecting intravenously an
ultrasound contrast agent containing small microbubbles and
intramyocardial contrast opaciﬁcation is visualized and recorded.
Absence of opaciﬁcation detects no reﬂow/dysfunctional micro-
vascular circulation. MCE is best recorded after 24–48 h after PPCI
since MCE performed immediately after PPCI may under estimate
the size and extent of no reﬂow.
6.5. Coronary magnetic resonance imaging (CMRI)
CMRI is regarded as the most sensitive and speciﬁc method to
assess the extent of no reﬂow. The ideal time to get the highest
predictive value of MRI is 1 week after myocardial infarction
although it can be done at 48–72 h after PCI. This a non-invasive
Gadolinium based technique performed in two steps (i) Early CMRI
is performed soon after injecting gadolinium and recorded during
the ﬁrst pass of the contrast agent and (ii) late or delayed contrast
enhanced MRI performed 10–20 min after the injection of contrast.
The early phase represent no reﬂow, while the delayed phase
depicts the extent of myocardial necrosis. CMRI is utilized to assess
(a) infarct size (IS) and (b) intramural hemorrhage (IMH).44
7. Prognostic implications of no reﬂow
No reﬂow portends a poor short term and long-term prognosis in
humans. The immediate clinical course in the hospital following no
reﬂow may be complicated with malignant arrhythmias, re-
infarction, cardiac rupture (in form of ventricular septal defect or
rupture of valve structure causing severe mitral regurgitation or even
left ventricle wall rupture) and pump failure.5 There is an increased
risk of death at 30 days with a relative risk (RR) of 2.1 (p < 0.038). The
effects of no reﬂow on left ventricle remodelling are equally adverse.
The end diastolic volume of left ventricle starts increasing after no
reﬂow and eventually results in LV dilation and reduced left ventricle
(LV) ejection fraction (EF) and heart failure. LV remodelling is almost
negligible in the absence of no reﬂow. Five-year hospitalization and
mortality is more common in no reﬂow patients.6,9
Ndreppa et al.9 studied the infarct size (IS) and mortality in
1406 STEMI patients, who underwent PPCI, which was followed by
no reﬂow in 410 and normal reﬂow in 996 patients. The infarct size
was measured by single photon emission computed tomography
(PET). The patients were followed with the aim of ﬁnding primary
outcome of 5-year mortality. The infarct size was 15% (6–29%) of
LV in no reﬂow group vs 8.0% (2–21%) of LV in normal ﬂow group
(p < 0.001). There were 59 deaths (14.3%) in no reﬂow group vs
73 deaths (7.3%) in normal reﬂow group. The Kaplan–Meier
estimates of 5-year mortality were 18.2% in no reﬂow group vs
9.5% in normal reﬂow group (p  0.001). The authors concluded
that no reﬂow was a strong predictor of 5-year mortality.
In a recent meta-analysis of 10 studies out of 134 publications
between January 2004 and April 2012, van Kranenbrug et al.45
concluded that microvascular obstruction is responsible for no
reﬂow, which is an independent predictor of MACE and cardiac
death at 2 years.
8. Management of no reﬂow
Optimal therapeutic strategies for the management of no-reﬂow
depend on the extent of structural and functional damage in anyindividual patient.10 In structural no reﬂow, the integrity of
microvessels is irreversibly damaged, while in functional no reﬂow,
the microvascular obstruction is characterized by a dynamic time
course and is potentially reversible. The therapeutic approach
should depend upon the prevailing mechanism of functional no
reﬂow. However, therapeutic drug may fail to reach the target lesion
due to prevailing obstruction. Hence prevention of no reﬂow is far
better than treatment. In humans, distal athero-thrombo-emboli-
zation has been recognized as the predominant mechanism for no
reﬂow. The various strategies to tackle thromboembolism are (i)
manual thrombus aspiration, (ii) mechanical thrombectomy, (iii)
direct stenting without prior ballooning and often combined with
prior thrombus aspiration, (iv) embolic protection devices and (v)
intracoronary abciximab. Ischemic (and reperfusion) injuries play a
devastating role in some patients. To avoid ischemic injuries, the
patient is to be prepared for PPCI at the earliest (preferably within
40–90 min). Prior to PPCI, full dose of aspirin (325 mg), atorvastatin
(80 mg) and antiplatelet therapy (prasugrel 60 mg or ticagrelor
180 mg or clopidogrel 600 mg) must be given. Newer P2Y12
receptor blockers (prasugrel and ticagrelor) are more powerful
antiplatelet agents and are preferred over clopidogrel in absence of
any contrainidication. Attempts should be made to stabilize and
control the prevailing risk factors (e.g. hyperglycemia, arrhythmia,
severe hypotension or acute heart failure).
9. Thrombus aspiration
Manual aspiration and mechanical thrombectomy have been
used successfully prior to stenting during PPCI in STEMI patients.
Various trials are summarized in Table 2.
9.1. Manual aspiration trials
1. REMEDIA (Randomized Evaluation of the Effect of Mechanical
reduction of distal Embolization by Thrombus Aspiration) Study
was conducted on 90 patients of STEMI presenting within 12 h
of chest pain. Thrombus aspiration by Pronto (vascular
solutions) improved MBG and STR.46
2. TAPAS Trial (Thrombus aspiration during primary coronary
Interventions)47: 535 STEMI patients underwent thrombus
aspiration by Export (Medtronic vascular) prior to PCI while
536 underwent conventional PCI without thrombus aspiration.
Assessment of MBG grading showed that thrombus aspiration
resulted in better reperfusion vs PCI alone (p < 0.001). One year
follow-up of TAPAS trial showed reduced mortality with better
ejection fraction in thrombus aspiration group.48
3. PIHRATE Trial (Polish Italian Hungarian Randomized Throm-
bectomy Trial): 196 STEMI <6 h underwent either thrombus
aspiration followed by direct stenting (n = 100) or balloon
dilatation and stenting (n = 96). Angiographic parameters of
microvascular reperfusion assessed by MBG grading were
superior in the thrombus aspiration group vs standard
ballooning followed by stenting (p < 0.001).49 Thrombus
aspiration followed by direct stenting was advised in this study.
4. TASTE Trial (Thrombus Aspiration during ST-segment Elevation
myocardial infarction): It was an open label prospective trial at
29 PCI centres in Sweden (11,709 patients) and one center each
in Iceland and Denmark (247 patients). Out of these
7244 patients were randomized for either thrombus aspiration
before PCI (n-3621) or conventional PCI (n-3623). Trial failed to
demonstrate any difference in mortality, recurrent myocardial
infarction and stent thrombosis at 30 days in the two groups.50
5. TOTAL Trial51: 10,732 STEMI patients undergoing PCI were
randomly assigned to either upfront manual thrombus aspira-
tion (n-5033) or PCI alone (n-5030). Trial showed no statistical
difference in the primary outcome of recurrent MI, heart failure,
Table 2
Randomized thrombectomy trials for the prevention of reperfusion no reﬂow.
(A) Manual thrombus aspiration
Trial Author Number of patients Results
1. REMEDIA Burzotta et al.46 99 Improved MBG and ST resolution
2. TAPAS Svilass et al.47
Vlaar et al.48
1071 Improved MBG and reduction in 30 days mortality
Reduced mortality at 1 year
3. PIHRATE Dudek et al.49 196 Aspiration thrombectomy and direct stenting is safe and effective
and results in better angiographic results with no difference in 6 months mortality
4. TASTE Frobert et al.50 11,709 No reduction in 30 days mortality, ST or recurrent MI
5. TOTAL Jolly et al.51 10,732 No reduction in mortality at 6 months, increased stroke at 30 days
(B) Mechanical thrombectomy
Trial Author Number of patients Results
1. JET stent study Migliorini et al.52 – Improved STR
Reduced MACE at 1 year
2. X-sizer (Ev 3) Lefevre et al.53 201 Improved ST resolution
MBG, myocardial blush grade. MI, myocardial infarction; STR, ST resolution; MACE, major cardiovascular event.
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However, there was an increase in the incidence of stroke at
48 h and 30 days in the thrombus aspiration group with high
mortality (30.8%) within stroke patients within 180 days.
9.2. Mechanical thrombectomy
1. ANGIOJET rheolytic thrombectomy
It involved delivery of pressured heparin saline (in the
coronaries), which travels backwards creating a low pressure
zone with powerful vacuum effect, drawing the thrombus into
the intra-coronary catheter. The recent randomized Jet Stent
Trial52 showed improvement in STR in the treated group,
followed by reduced MACE on 1-year follow-up. Angiojet
procedure is, however, complex and routine rhelotytic throm-
bectomy prior to PCI is not beneﬁcial.
2. X-SIZER (EV-3 Plymouth): X-AMINE TRIAL
Use of X-sizer device in X-AMINE Trial reduced the distal
embolization and improved ST resolution.53 However MBG and
6 months MACE and mortality did not show any beneﬁt.
9.3. Infuse AMI trial (intracoronary bolus abciximab)54
In a randomized trial, 452 patients due to occlusion of left
anterior descending artery (LAD) with large anterior wall
myocardial infarction were studied at 37 sites in 6 countries,
presenting within 4 h of STEMI. The patients were divided into
2 groups: (i) thrombectomy group (n-174) vs no thrombectomy
group (n-179) and (ii) abciximab group (n-181) vs no abciximab
group (n-172). Abciximab was administered by an intracoronary
catheter (Clearway) at the site of lesion/infarct. The end point was
the measurement of infarct size (IS) assessed by cardiac MRI at
30 days. There was a signiﬁcant reduction of IS in abciximab group
and not in thrombectomy group. Infuse AMI Trial was further
analyzed comparing IS with successful MBG (2/3) vs those with
unsuccessful MBG (0–1). Abciximab reduced infarct size (IS) by
30% in patients with successful MBG (2/3) and reduced mortality
with improvement in left ventricular ejection fraction (EF) at
30 days (Brenner et al.).55
10. Meta-analysis studies
Various randomized trials on thrombus aspiration, mechanical
thrombectomy and embolic protection trials have undergone
meta-analysis by various authors. The results of these trials are atvariance. These trials are summarized in Table 3. Following
conclusions were drawn from these meta-analyses.
1. Manual thrombus aspiration is simpler and superior to
mechanical thrombectomy and is associated with reduced
MACE at 6–12 months.56,57,62
2. Manual thrombus aspiration may be beneﬁcial in improving
MBG and TIMI ﬂow 3 but was not associated with reduced MACE
and mortality at 6–12 months.58–61
3. Two recent meta-analysis by Jolly et al.63 and Elgendy et al.64
have raised doubt about the beneﬁcial effect of thrombectomy
on mortality. There is an additional risk of stroke.
11. Guidelines on STEMI and myocardial reperfusion
The guidelines on management of STEMI and myocardial
reperfusion have been issued by European Society of Cardiology
(ESC) (2012)65 and European Association of cardio-thoracic
surgery (EACTS) (2014).66 The guidelines have also been issued
by American College of Cardiology (ACC), American Heart
Association (AHA) and Society of Cardiovascular Interventions
(SCAI) (2011, 2013).1,67 However, keeping in mind the newer
information and observations of TASTE, TOTAL and INFUSE AMI
trials and recent meta-analysis on thrombectomy by Jolly et al. and
Elgendy et al., ACC/AHA/SCAI have recently modiﬁed their earlier
recommendation as given below (Levine et al.).68
2011/2013
recommendation
2015 focused update
Recommendations
Comments
Class IIa
Manual aspiration
thrombectomy is
reasonable for
patients
undergoing
primary PCI
(Level of Evidence: B)
Class IIb
The usefulness of selective
and bailout aspiration
thrombectomy in patients
undergoing primary PCI
is not well established
(Level of Evidence: C-LD)
Modiﬁed recommendation
(Class changed from ‘‘IIa’’
to ‘‘IIb’’ for selective and
bailout aspiration
thrombectomy before PCI)
Class III: No Beneﬁt
Routine aspiration
thrombectomy before
primary PCI is not useful
(Level of Evidence: A)
New recommendation
(‘‘Class III: No Beneﬁt’’
added for routine
aspiration thrombectomy
before PCI)
PCI, percutaneous coronary intervention; LD, limited data.
12. Direct stenting
The dilatation of coronary artery prior to stenting may result in
dislodgement of atheromatous debris from thrombus and cause
Table 3
Meta-analysis of randomized studies on thrombectomy vs PCI alone.
Author Number of trials analyzed Number of patients Follow-up period Results
1. Bavry et al.56 30 6415 6 months Aspiration thrombectomy reduced
mortality while mechanical
thrombectomy and distal embolic
protection did not reduce mortality
2. Burzotta et al.57 11 2686 1 year Manual thrombectomy improved 1 year
survival. Additional beneﬁt when
patients treated with IIb/IIIa antagonist
3. Mongeon et al.58 21 4299 30 days Mortality up to 30 days not reduced
although ST resolution was better
No reduction in recurrent MI/stroke
4. Tamhane et al.59 8 – manual device (Export, Pronto, Diver)
5 – mechanical device (Angiojet, X-Sizer)
4 – vacuum (Rescue TVAC)
3909 30 days 30 days mortality not reduced although
MBG and TIMI ﬂow 3 improved
Stroke incidence increased in
thrombectomy (14/1403) vs PCI alone
(3/1413)
5. De Luca et al.60 21 4514 30 days Manual thrombectomy improved ST
resolution but did not reduce mortality
Higher risk of stroke in thrombectomy
patients within 30 days
6. Jolly et al.63 20
10
21,173
19,585
180 days
180 days
Mortality 3.8% in thrombectomy group
vs 4.3% in PCI only group
Stroke in thrombectomy group was 0.8%
vs 0.5% in PCI only group
7. Elgendy et al.64 17 20,960 – (1) No signiﬁcant reduction in death, re-
infarction with routine aspiration
thrombectomy
(2) Additional risk of stroke
8. Kumbhani et al.62 18 – manual aspiration
7 – mechanical thrombectomy
3936
1598
Total 5534
12 months Manual aspiration but not mechanical
thrombectomy beneﬁcial in reducing
MACE and mortality at 6–12 months
9. Deng et al.61 26 11,780 24 months No evidence of deﬁnite beneﬁt by
manual aspiration although MACE was
less frequent
MI, myocardial infarction; MBG, myocardial blush grade; TIMI, thrombolysis in myocardial infarction; PCI, percutaneous coronary intervention.
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balloon dilatation has been advised to reduce the incidence of no
reﬂow. However, direct stenting without prior ballooning may be
difﬁcult. More over the results of direct stenting have been
controversial.
Dudek et al.49 have advocated direct stenting following
thrombus aspiration (PIHRATE Trial) resulting in better microvas-
cular perfusion assessed by MBG.
13. Deferred stenting
Deferred stenting in selected high risk patients may reduce the
incidence of no reﬂow.69 During the deferred period of 6–12 h, the
patient is treated in intensive coronary care unit (ICCU) and
receives supportive therapy. In a recent randomized study of
411 STEMI patients, the results of deferred stenting were
compared with immediate stenting.70 The authors concluded that
in high risk STEMI patients deferred stenting reduced incidence of
no reﬂow as judged by TIMI ﬂow grade and cardiac MRI.Table 4
Trials on M-guard stent.
Name of trial/author Number of patient FU
Non-randomized trial
1. Piscione et al.71 100 24
2. MAGICAL (Dudek et al.)72 60 36
3. REWARD MI (Fernandez Gisnal)73 150 10
Randomized trials
1. MASTER I (Stone et al.)74
(Costa et al.)75
433 12
2. MASTER II (Gracida et al.)76 Designed for 1114 patients
but trial stopped in middle
3014. M-guard stent
M-guard stent is a new technology. The M-guard stent design is
built to prevent distal embolization and no reﬂow following PCI. It
consists of a bare metal stent with cobalt chromium strut with
polyethylene theraphthalate mesh (micronet) covering anchored
to the external surface of the strut. M-guard has undergone three
non-randomized and two randomized trials. The results are
summarized in Table 4. Piscione Trial71 was a multicentric Italian
prospective registry of 100 patients. Full revascularization was
achieved in 90% patients with a MACE of 7.9% and mortality of 7%.
MAGICAL trial72 enrolled 60 patients with almost similar results.
REWARD MI trial73 is a recent retrospective study of 150 patients
with good results. The randomized MASTER I Trial involved
433 patients.74,75 M-guard stenting was particularly beneﬁcial in
STEMI patients with large thrombus burden, restoring myocardial
reperfusion and reducing no-reﬂow. However, M-guard stent has
exhibited three drawbacks: (i) frequent instent restenosis due to
bare metal strut, (ii) inability to reach or cross the lesion (4.1%) and STR > 70% MBG 3 Side effects
 months 90% 90% MACE – 7.9%
 months 61% 90% Mortality – 7%
 months 86% 74% –
 months 57.8% 74% Stent dislodgement (0.9%)
Instent restenosis
 days 56.9% – M-guard stent withdrawn
in 2015
Table 5
Pharmacologic strategies for no reﬂow.
Drug Route Dose Side effects
1. Adenosine78–86 IC, IV IV: 70 mg/kg/min  3 h
IC: 48–200 mg bolus
Transient heart block, hypotension,
bronchospasm
2. Nicorandil93–96 IC, IV IV: 8 mg/h infusion
IC: 2 mg bolus
–
3. Sodium nitroprusside97–100 IC 50–200 mg bolus Hypotension
4. Calcium channel drugs87–92
(a) Verapamil IC 100–250 mg bolus or 100 mg/min up to 1000 mg Hypotension, heart block
(b) Diltiazem IC 400 mg –do–
(c) Nicardipine IC 50–200 mg bolus (upto 500 mg) –do–
5. Abciximab101,104,105
Eptiﬁbatide103
Tiroﬁban102
IC
IV
IV
IV
IC: 0.25 mg/kg bolus
IV: 0.25 mg/kg bolus followed 0.125 mg/kg/h
2 mg/kg/min
IV: 10 mg/kg
Bleeding
6. Epinephrine122 IC 50–200 mg Arrhythmias
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to failure to cross (0.9%). There is not data for side branch occlusion,
though there is a theoretical risk due to stent design. In view of
above the manufacturers decided to cancel the MASTER II Trial and
recall the M-guard stents. The manufacturers are now trying to
develop a new drug eluting version of M-guard stent.76
15. Pharmacological treatment of no reﬂow
Pharmacological drug management has been the sheet anchor
of modern therapy utilized by interventional cardiologist in the
cath lab to manage no reﬂow in acute setting. Drugs are
administered by intracoronary route and delivered directly into
the IRA by guiding catheter or through infusion catheters, since the
drugs given intravenously may not reach the target site due to
microvascular obstruction in no reﬂow. Distal infusion catheter
(Clear way Medical Corporation, USA) and Multifunction Probe
catheter (Boston Scientiﬁc, MA) are the two most suitable
catheters for drug administration at the target site.77 Pharmaco-
logical strategies are summarized in Table 5.
16. Adenosine
Adenosine is a potent vasodilator. It inhibits neutrophil adhesion
and migration and reduces formation of oxygen free radicals.
Adenosine was administered intravenously in AMISTAD I (Acute
Myocardial Infarct STudy of ADenosine) as infusion of 70 mg/kg/min
for 3 h in 236 STEMI patients in a randomized fashion.78 Adenosine
reduced the infarct size (IS) measured by SPECT in 33%. In AMISTAD II
study, adenosine was administered as IV infusion (50 mg/kg/min or
70 mg/kg/min) in a randomized study of 2118 patients.79 The
infusion was started 15 min before PCI and continued for 3 h. The
study conﬁrmed the reduction of infarct size (IS) but follow-up
results on MACE and mortality were inconclusive.
Adenosine has also been administered by intracoronary (IC)
route (dose 24–48 mg as bolus) in no reﬂow patients and found
effective.80 REOPEN TRIAL evaluated intracoronary adenosine or
nitroprusside.After thrombus aspiration in 240 STEMI patients
during PCI with upstream infusion of GpIIb/IIIa.81 The patients
were randomly divided into 3 groups: (i) adenosine group (n = 80)
given IC 120 mg bolus followed by 2 mg in 33 ml saline slow
infusion over 2 min, (ii) nitroprusside group (n = 80) given 60 mg
bolus followed by 100 mg in 33 ml 5% glucose slow infusion over
2 min and (iii) placebo group (n = 80) in which 33 ml saline was
given over 2 min. STR >70% at 90 min was found in 71% adenosine
vs 54% in nitroprusside vs 51% in saline group. 30 days MACE (heart
failure and recurrent MI) was 10% in adenosine group vs 14% in
nitroprusside group and 20% in saline group. The authors
concluded that adenosine was more beneﬁcial than nitroprusside.More recently 46 STEMI patients, who had developed no reﬂow
following PCI received IV Tiroﬁban and then randomized into three
groups: adenosine (n = 16), verapamil (n = 15) and placebo (n = 15)
depending upon IC drug administered.82 In this trial adenosine was
not found beneﬁcial, while verapamil was effective. REFLOW
STEMI is an ongoing trial to compare the effects of adenosine,
nitroprusside and placebo. Primary end point is the measurement
of infarct size at the end of 48–72 h by CMRI. The results are
awaited.
Su et al.83 made an updated search of 11 RCTs involving
1027 STEMI patients. 10 RCTs evaluated adenosine only. There was
no evidence that adenosine reduces short term or long term all
cause mortality or recurrent myocardial infarction. Adverse effects
of adenosine were bradycardia, hypotension and atrioventricular
block. However adenosine as treatment did reduce angiographic
no reﬂow. Gao et al.84 performed a PRISMA COMPLAINT meta-
analysis and extracted the data from 15 RCTs with 1736 patients.
Data revealed that there was better STR and improved TIMI ﬂow
grade after adenosine but no deﬁnite improvement in LVEF or
mortality.
Adjedj et al.85 have recently studied intracoronary adenosine
dose-dependent relationship with hyperaemia in 30 patients by
measurement of Doppler derived coronary ﬂow velocity (CFV). The
optimal IC bolus dose of adenosine was 100 mg in right coronary
artery (RCA) and 200 mg in left coronary artery (LCA) to induce
maximum hyperemia and with minimal side effects. No reﬂow and
infarct size depend upon the dose of adenosine (Yetgin et al.).86
17. Calcium channel blockers
Verapamil, diltiazem and nicardepine have been studied for
their beneﬁcial effects in no reﬂow. These drugs act by blocking L-
type channels in the cell membrane of myocardium and cause
endothelial dependent relaxation of micro-vessels. These also
reduce oxygen demand by the myocardium and minimize the
damage caused by oxygen free radicals. Verapamil was adminis-
tered by intracoronary route through coronary infusion catheter
distal to the stent in dose of 100–250 mg as bolus followed by
100 mg/min infusion till a maximum of 1000 mg (1 mg) in 23 STEMI
patients with no reﬂow.87 TIMI ﬂow improved in 87% patients
along with reduction of corrected TIMI frame count (CTFC) (from
56  9 to 24  4, p < 0.0001). In a randomized study of 150 STEMI
patients, verapamil and adenosine were equally effective for
prevention of no reﬂow and improving TIMI frame count.88 In
RECOVER AMI trial, 102 patients of no reﬂow were randomly divided
in 3 groups: (i) verapamil (n = 34), (ii) diltiazem (n = 34) and (iii)
nitroglycerine (n = 34). Diltiazem given via intracoronary route (dose
400 mg diluted in normal saline) followed by 90 mg orally bd in the
ward. The end results were measured by CTFC 3 h after PCI. There was
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Verapamil was administered in dose of 100–200 mg by intra-coronary
route immediately after the diagnosis of no reﬂow in 25 patients
(with TIMI ﬂow <2).90 21 patients (84%) responded with TIMI ﬂow
3. Two patients developed transient hypotension, which reversed in
3–5 min. Three patients developed severe bradycardia, which also
reversed by intravenous atropine (0.5–1 mg). In a recent meta-
analysis, Wang et al.91 analyzed 8 RCTs with 494 patients (162 on
drug and 163 as control) treated with verapamil or diltiazem, which
equally decreased no reﬂow signiﬁcantly (RR 0.3, 95% CI: 0.16–0.57,
p = 0.0002) and reduced CTFC (weighted mean difference = 9.24,
95% CI: 13.91–4.57, p = 0.0001). In addition, verapamil and diltiazem
improved wall motion abnormality and reduced 6 months MACE.
However both drugs did not provide additional improvement in left
ventricular ejection fraction (EF) at 6 months.
Nicardepine by intracoronary route (dose 360–460 mg) was
administered to 72 patients of no reﬂow.92 71 patients responded
to the treatment with nicardipine. TIMI ﬂow grade improved from
a mean of 1.65  0.53 to 2.97  0.24 (p < 0.001) and CTFC reduced
from 57  40 to 15  12 (p < 0.0001). The drug was well tolerated.
Thus all three calcium channel blockers have produced good
results in the treatment of no reﬂow.
18. Nicorandil
Nicorandil is an ATP-sensitive potassium channel opener and a
nitric oxide (NO) donor. It modulates neutrophil activation and
suppresses formation of oxygen free radicals. It is a potent
vasodilator. It reduces reperfusion injury and promotes blood ﬂow
velocity in the coronaries. It improves LV function and reduces
endothlin-1 (ET-1) in no reﬂow patients (Chen et al.).93 Nicorandil
has been found beneﬁcial in the prevention and treatment of no
reﬂow94 and reducing major cardiac adverse events (MACE) at
5 years.95 Nicorandil has been used as IV infusion 8 mg/h or as
intracoronary bolus (2 mg).96
19. Sodium nitroprusside
It is a direct donor of NO which is a potent vasodilator. The dose
has to be carefully balanced against induced hypotension. It was
administered by intra-coronary route (100 mg bolus) in 11 STEMI
patients with no reﬂow and was found effective in 82% cases.97
Better angiographic reperfusion (assessed by TIMI ﬂow) was found
in 70 no reﬂow patients, when IC nitroprusside (50 mg) was
combined with adenosine (12 mg) as bolus.98 However Amit
et al.99 found negative results on the prevention of no reﬂow in a
randomized study of 98 STEMI, when sodium nitroprusside was
given intra-coronary route in bolus dose of 60 mg and results
assessed by CTFC, MBG and STR. A recent retrospective randomized
study evaluated the effects of nitroprusside (n = 43) or throm-
bectomy (n = 124) vs control (n = 97 patients). Thrombectomy
provided improved perfusion grade assessed by TIMI ﬂow
compared with early intracoronary administration of nitroprus-
side. Neither thrombectomy nor nitroprusside had any signiﬁcant
impact on 30 days, 1 year and 3 year MACE or survival (Lee
et al.).100
20. Glycoprotein IIB/IIIA inhibitors
These are modern potent antiplatelet drugs. Abciximab,
tiroﬁban and eptiﬁbatide have been used for the prevention and
treatment of no reﬂow. In a study of 90 STEMI patients, no reﬂow
occurred less frequently in abciximab group (7%) compared with
control group (17%).101 Tiroﬁban given as upstream intravenous
infusion achieved better STR and MBG following PCI in ON TIME
TRIAL.102 Eptiﬁbatide administered in PROTECT TIMI studyimproved reperfusion by TIMI ﬂow grading in PROTECT TIMI
trial.103
A recent randomized trial of IC vs IV abciximab demonstrated a
signiﬁcantly smaller infarct size (15.1% vs 23.4%, p = 0.001) as
assessed by CMRI.104 In a much larger study (AIDA-STEMI), an open
label multicentre trial,105 2065 STEMI patients presenting within
12 h with no contraindication to abciximab were randomly
assigned intracoronary abciximab (n-1032)(bolus dose 0.25 mg/
kg) or intravenous abciximab (infusion dose 0.125 mg/kg/min)
(n = 1033). The intracoronary or intravenous abciximab did not
result in any difference in the combined end point of death, re-
infarction or congestive heart failure. Since IC abciximab bolus is
safe, it may be preferred if abciximab is indicated. ESC/EACT
guidelines (2014) recommends use of GpIIb/IIIa as a bail out
procedure in no reﬂow patients.66
COCTAIL TRIAL (2015)106: the safety and efﬁcacy of IC cocktail
injection combined with thrombus aspiration in STEMI patients
treated with primary PCI are under study. The cocktail includes
bivalirudin, tiroﬁban and tenectaplase. The trial is sponsored and
conducted at Xijing Hospital, China. The trial is currently recruiting
participants and the results are still awaited.
COCTAIL II study has compared standard vs CLEARWAY infused
abciximab in myocardial infarction.107
21. Ranolazine (RWISE trials)
Ranolazine is an inhibitor of late sodium current. RWISE was a
randomized trial of ranolazine in patients with coronary micro-
vascular dysfunction (Bairey Merz et al.).108 In this trial ranolazine
did not improve myocardial perfusion index or the quality of life.
22. Pre-conditioning and post-conditioning
When subjected to non-lethal periods of ischemia, heart may
adapt to become more resistant to a subsequent more severe acute
ischemia or infarction. The cardiac adaptation is termed as
ischemic pre-conditioning.109 Patients with pre-infarction angina
may exhibit better clinical outcome and smaller infarct size.
Ischemia post-conditioning is another similar concept of cardiac
adaptation.110 Ischemic pre- and post-conditioning have been
further elaborated.111,112 Ischemic conditioning probably exerts
their protective effect via their action on the mitochondrial
permeability pores. The concept needs further research.
23. Newer drugs and prospectives under investigation
1. Immunosuppressive ex. cycloserine inhibits opening of mito-
chondrial permeability transition pores and improves LVEF. It
may reduce infarct size.113
2. Bendavia: a mitochondria cytoprotective peptide (EMBRACE
STUDY): may reduce ischemic reperfusion injury.114
3. Atrial natriuretic peptide (ANP) acts via cardioprotective path-
ways and reduced IS with improved LVEF in J-Wind trial.115
4. Exenatide given 15 min before PCI and 6 h post-PCI improved
salvage index.116
5. FX 06 (FIRE STUDY): a peptide from human ﬁbrin failed to
reduce IS and MVO, although FX06 reduced necrotic core
zone.117
6. Pexelizumab, a Humanized mono-component antibody that
binds the C5 component was administered as 2.0 mg/kg bolus,
or 2.0 mg/kg bolus and 0.05 mg/kg infusion. It reduced 90 days
mortality but had no measurable effect on infarct size in
COMMA TRIAL.118 Pexelizumab was investigated as an adjunct
to PCI in improving 30 and 90 days mortality, cardiogenic shock
or heart failure in APEX AMI trial but failed to show any
beneﬁt.119,120
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administered as an adjunct to early reperfusion therapy for
acute myocardial infarction in ESCAMI trial.121 It was given in a
dose of 50–200 mg as an infusion over 10 min prior to PCI.
Eniporide did not make any signiﬁcant difference in the clinical
outcome.
8. Epinephrine has been administered for the treatment of
noreﬂow, when all other drugs have failed and the patient
remains critically unstable. However the RESTORE-SIRIO trial
with epinephrine in no-reﬂow was prematurely withdrawn
(2016).122
9. Miscellaneous drugs – antioxidants, statins, endothelin receptor
antagonist and Thromboxane A2 receptor antagonist may have a
role to protect against no reﬂow.Fig. 2. Flow chart: manag24. Conclusions
Diminished and impaired myocardial reperfusion despite
successful opening and patency of infarct related artery (IRA) in
STEMI following PCI is known as no reﬂow phenomenon. It may set
in and manifest soon after ballooning or stenting during PCI in the
cath lab (or ICCU). No reﬂow is a multifactorial phenomenon.
Micro-embolization, ischemia and reperfusion injuries are the
principal mechanisms responsible for no reﬂow. In cath lab, it is
diagnosed by ﬁnding TIMI ﬂow <3 or TIMI ﬂow 3 with MBG 0–1 or
by direct measurement of coronary ﬂow reserve (CFR) using
intracoronary guidewire. Failure of STR <70% (60 min after PCI)
can be an indicator of no-reﬂow in the ICCU. The extent of cardiac
damage is judged by cardiac MRI. Currently there is no consensusement of no reﬂow.
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been recognized and prevention is always better than treatment.
Measures to reduce time interval from onset of chest pain to PPCI
are probably the best measure to improve myocardial salvage and
reduce risk of no reﬂow. Flow chart (Fig. 2) may help in deciding
the steps to be undertaken at various stages of treatment. No-
reﬂow may present as an emergency in cath lab with adverse
prognosis. Such patients warrant urgent supportive measures to
save life. Intracoronary adenosine, calcium channel blockers,
nicorandil, nitroprusside or GpIIb/IIIa are administered depending
upon the underlying mechanism/s and the choice of interventional
cardiologist. Manual aspiration thrombectomy may have limited
effectiveness in patients with large thrombus burden. Unfortu-
nately no reﬂow may prove resistant to pharmacological therapy in
5–10% cases, with adverse short term and long term outcomes. A
personalized attention to tide over the crisis in cath lab is required
for every patient of no reﬂow.
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